Barclays' Mixed Bag
Barclays has joined the pack of banking earnings bonanzas this results season — or at least on the face of it.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
13 minutes ago
- Forbes
Sell HIMS Stock Ahead of Its Earnings?
Hims & Hers Health (NYSE:HIMS) is set to announce its earnings on Monday, August 4, 2025. Historically, HIMS stock has reacted unfavorably to earnings announcements. Since 2021, the stock has recorded a negative one-day return in 53% of instances after results. The median one-day decline has amounted to -5.8%, with a maximum one-day decrease of -22.3%. For traders focused on events, grasping these historical trends can be beneficial. While the actual results compared to consensus and expectations will be vital, there are two main strategies to contemplate: Analysts expect HIMS to report earnings of $0.23 per share on revenues of $552 million. This would mark substantial growth compared to the same quarter last year, which recorded earnings of $0.16 per share on revenues of $315 million. A possible positive factor for Hims & Hers' sales growth momentum is the reported underperformance of Novo Nordisk's weight loss medication in the U.S. due to the presence of compounded versions. Regarding fundamentals, HIMS has a market capitalization of $15 billion. Over the past twelve months, the company generated $1.8 billion in revenue and was operationally profitable, reporting $110 million in operating profits and a net income of $164 million. However, if you're looking for upside with less volatility than individual stocks, the Trefis High Quality portfolio offers an alternative — it has outperformed the S&P 500 and achieved returns exceeding 91% since its inception. Additionally, see – Is There More Upside For MSFT Stock? Review earnings reaction history of all stocks HIMS Stock Historical Likelihood of Positive Post-Earnings Return Here are some insights on one-day (1D) post-earnings returns: Additional information regarding the observed 5-Day (5D) and 21-Day (21D) returns post earnings is summarized along with the statistics in the table below. HIMS Stock Correlation Between 1D, 5D, and 21D Historical Returns A comparatively lower-risk strategy (though not effective if the correlation is weak) is to understand the relationship between short-term and medium-term returns post earnings, identify a pair that has the highest correlation, and perform the corresponding trade. For instance, if 1D and 5D exhibit the highest correlation, a trader can take a "long" position for the next 5 days if the 1D post-earnings return is positive. Here is some correlation information based on a 5-year and 3-year (more recent) timeframe. Note that the correlation 1D_5D denotes the relationship between 1D post-earnings returns and subsequent 5D returns. Discover more about the Trefis RV strategy that has outperformed its all-cap stocks benchmark (a blend of the S&P 500, S&P mid-cap, and Russell 2000), delivering strong results for investors. Additionally, if you seek upside with a smoother experience than an individual stock like Hims & Hers Health, consider the High Quality portfolio, which has surpassed the S&P and yielded >91% returns since its inception.
Yahoo
22 minutes ago
- Yahoo
BT, EE and Plusnet announce new price rises
BT and EE have raised mid-contract price rises for customers taking out a new deal from Thursday. New BT and EE customers who sign up for broadband from July 31 will see their monthly price rise by £4 mid-way through their contract. This will come into effect on March 31 next year, then again on the same date in 2027. The previous mid-contract price rise was £3 a month. Meanwhile, Plusnet customers will also be subject to a mid-contract price rise of £4 a month from August 5. EE, BT and Plusnet mobile customers will also be hit with higher mid-contract price rises. Those who are a Sim-only or Flex Pay customer will see their contract price rise by £2.50 a month from April, while bundled handset and airtime plan customers will face a £4 rise. A BT consumer spokesman said: 'We are very supportive of Ofcom's requirement to show upfront pounds and pence charges. EE was the first provider to introduce this pricing model, offering EE customers a predictable long-term view of their contract terms. Our pricing approach is designed to be clear for our customers. 'We continue to invest in our business, building on 11 years as the best network to better serve our customers with a reliable and quality connection as we roll out the fastest speed technology to 30 million homes by the end of the decade. We're focused on providing value and customer satisfaction, making new technologies available to our customers such as 5G standalone and WiFi 7.' Ernest Doku, telecoms spokesman at said: 'In another pounding for consumers' wallets, BT, EE and Plusnet will hike mid-contract price rises to £4 per month for broadband and EE £2.50 per month for some mobile customers. 'This adds an extra £1 to mid-contract price rises for new and recontracting customers signing up from 31 July 2025 for EE and BT and 5 August 2025 for Plusnet. 'BT's price updates have often set a precedent for other providers to follow suit. If this trend continues, the telecoms industry runs the risk of creating its own, accelerated rate of inflation.' Mr Doku added: 'Based on our research, where the average BT customer pays £31.50, EE customer £29.20 and Plusnet customer £25.80 for home broadband, this represents a staggering rise of between 12.6% and 15.5% – significantly higher than current inflation of 3.6%. 'From 31 July, EE Sim-only and Flex Pay airtime mobile customers signing up for new deals will see a £2.50 monthly increase applied in March 2025. For those taking out EE's cheapest £18 per month Sim-only plan, this is the equivalent of a notable 13.8% hike. 'This change only applies to customers taking out new contracts, so if you are currently a BT, Plusnet or EE customer and your plan is up for renewal before March 2026 you should shop around for other options. Many regional broadband providers such as YouFibre and Trooli and mobile providers including Lebara and Smarty don't raise prices mid-contract.' Which? director of policy and advocacy Rocio Concha said: 'It's shocking that BT is choosing to increase its mid-contract price rises above the rate of inflation for any new customers who sign up for broadband packages from BT, EE or Plusnet from 31st July. 'Any out-of-contract BT, EE and Plusnet customers who aren't happy with these hikes should vote with their feet and switch to a cheaper deal. 'We'd always recommend carefully weighing up the total costs of any new contract to ensure it offers value for money and you're aware of any possible increases.' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Why AbbVie Stock Slumped Today
Key Points It had a good second quarter, fueled by sales growth in top blockbuster drugs. It also topped analyst estimates for both revenue and profitability. 10 stocks we like better than AbbVie › Shares of AbbVie (NYSE: ABBV) were bouncing along merrily for most of Thursday's trading session, until news of a fresh demand from the White House quashed the rally. Initially, the market was cheered by better-than-expected quarterly results published by the company that morning. Ultimately AbbVie's stock closed down slightly lower in price, roughly mirroring the trajectory of the S&P 500 index. Second-quarter rises That late-session swoon was kind of a shame, because AbbVie's second quarter boasted some good fundamentals. Total revenue came in at just over $15.4 billion, an increase of almost 7% over the year-ago result. Of its blockbuster drugs, Skyrizi did quite well, with sales rising 62% to $4.4 billion. Rinvoq also rocketed higher, by 42% to more than $2 billion. On the other hand, the fading Humira -- now that it's been subject to competition by biosimilars -- fell by 58% to less than $1.2 billion. As for net income, on a non-GAAP (adjusted) basis it landed at nearly $5.3 billion, or $2.97 per share. That was well up from the year-ago profit of $4.7 billion. On average, the pundits tracking AbbVie stock were collectively expecting a shade under $15 billion for revenue, and $2.96 per share for adjusted profitability. AbbVie raised its bottom-line guidance for the entirety of 2025. It now believes adjusted net income will amount to $11.88 to $12.08 per share, up from the previous estimate of $11.67 to $11.87. Trump's new move The bullishness generated by those fundamentals and the lifted guidance was tempered by the latest demand from President Donald Trump. Thursday afternoon, news broke that he sent letters to a clutch of major U.S. pharmaceuticals insisting that they reduce prices for prescription drugs within 60 days. One of the letters was sent to AbbVie CEO Rob Michael. In it, Trump wrote, "Right now, brand name drug prices in the United States are up to three times higher on average than elsewhere for the identical medicines." "This unacceptable burden on hardworking American families ends with my administration," the president added. Should you buy stock in AbbVie right now? Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie. The Motley Fool has a disclosure policy. Why AbbVie Stock Slumped Today was originally published by The Motley Fool Sign in to access your portfolio
